Patent ID: 8889875

Claim:
A method of treating a condition, disease, or disorder in a patient implicated by CFTR, wherein the condition, disease, or disorder is selected from cystic fibrosis, hereditary emphysema COPD, and dry-eye disease, comprising the step of administering to said patient a compound of or a pharmaceutically acceptable salt thereof, wherein: R N is H, or alkyl; A is an optionally substituted 3 membered monocyclic ring; B is optionally fused to a 5-7 membered ring selected from the group consisting of cycloaliphatic, aryl, heterocyclic, and heteroaryl; R 1 is halo, alkyl, OH, alkoxy, thioalkyl, trifluoromethoxy; or two R 1 on adjacent atoms, taken together, form wherein J is selected from the group consisting of CH 2 , CF 2 , or C(CH 3 ) 2 ; W is independently-a (C1-C6) alkylidene chain wherein up to two methylene units of W are independently replaced by —O—, —S—, —SO 2 —, or —NR′—; R′ is independently H, alkyl, aryl, heteroaryl, aralkyl, cycloalkyl, or heterocyclic; R W is independently H, halo, CN, NO 2 , N(R) 2 , CF 3 , OCF 3 , OH, OR, C(O)R, CO 2 R, C(O)N(R) 2 , —O(C1-C6)alkylidene-OR, —O(C1-C6)alkylidene-N(R) 2 , —O(C1-C6)alkylidene-heterocyclic, or an optionally substituted aliphatic, cycloaliphatic, aryl, aryloxy, heterocyclic, or heteroaryl, wherein, when substituted, R w is substituted with up to two R 2 ; R 2 is halo, CN, NO 2 , CF 3 , OCF 3 , OR, OC(O)R, OC(O)N(R) 2 , SR, S(O)R, SO 2 R, SO 2 N(R) 2 , SO 3 R, C(O)R, CO 2 R, C(O)N(R) 2 , N(R) 2 , NRC(O)R, NRCO 2 R, NRC(O)N(R) 2 , NRSO 2 R, B(OR) 2 , or NRSO 2 N(R) 2 ; R is independently H, alkyl, cycloalkyl, heterocyclic, aryl, or heteroaryl; n is 1 or 2; w is an integer from 1 to 4 inclusive; and x is an integer from 1 to 5 inclusive.